Grail, a pioneering firm in early cancer detection, has faced recent market volatility, seeing its stock price decline significantly from its January peak of $116.06 to below $70. This drop followed the news that its flagship Galleri blood test did not meet the primary endpoint in a crucial NHS England trial. However, the company's continued revenue generation and the long-term potential of its diagnostic technology warrant a closer look into its current investment standing.
The company, which was spun off from Illumina in 2024, developed the Galleri blood test, designed to identify early cancer signals before overt symptoms emerge. This innovation holds immense promise for transforming oncology by enabling earlier intervention. The recent trial's outcome was a blow, as it was considered a vital step towards securing FDA approval in the United States, which would pave the way for broader insurance and Medicare coverage.
Despite the setback in the NHS England trial, Grail has maintained various revenue streams. The Galleri test is currently available on a direct-pay basis, priced between $749 and $949, to individual consumers, select employers, hospital pilot programs, and telehealth services. Furthermore, the trial, while not meeting its primary goal, did show positive indicators: Galleri users experienced fewer Stage IV cancer diagnoses, and the test demonstrated earlier detection (Stage I and II) for some of the most aggressive cancers.
Financial analysts project that Grail's revenue will grow from $147 million in 2025 to $281 million by 2028. While the company is not expected to achieve profitability in the near term, and its current valuation at 17 times this year's sales appears steep, a future FDA approval could dramatically boost these revenue estimates. The innovative nature of its technology and its potential to revolutionize cancer care suggest that holding Grail's stock at its current suppressed price may be a prudent strategy, rather than a quick divestment.
In conclusion, while Grail's stock has experienced a recent downturn due to trial results, its foundational technology for early cancer detection remains highly promising. The company's ability to generate revenue even without immediate regulatory approval, coupled with the potential for future breakthroughs, suggests that its current valuation may present a strategic opportunity for long-term investors.